Heron Therapeuti (US:HRTX) — Company Overview, News & Financial Data
Heron Therapeutics develops innovative pain management and oncology treatments to address unmet medical needs.
Heron Therapeuti
Heron Therapeutics (NASDAQ:HRTX) specializes in developing innovative treatments aimed at addressing unmet medical needs in pain management and oncology. Their portfolio includes advanced therapeutics designed to improve the lives of patients undergoing surgery or those facing challenging cancer treatments. Heron is dedicated to pushing the boundaries of science to create solutions that can significantly enhance patient care and outcomes. Their objectives focus on advancing their research and development pipeline, ensuring the accessibility of their therapies, and maintaining a strong commitment to ethical practices and sustainability in all their operations.
Snapshot
Operations
Products and/or services of Heron Therapeuti
- CINVANTI for chemotherapy-induced nausea and vomiting
- ZYNRELEF for postoperative pain management
- SUSTOL for delayed chemotherapy-induced nausea and vomiting
- HTX-011 for postoperative pain
- APF530 for chemotherapy-induced nausea and vomiting prevention
- HTX-034 for postoperative pain management
Heron Therapeuti executive team
- Mr. Craig Alexander CollardCEO & Director
- Ms. Ira DuarteExecutive VP & CFO
- Dr. William P. Forbes Pharm. D., Pharm.D.Executive VP & Chief Development Officer
- Mr. Mark E. HensleyExecutive VP & COO
- Melissa JarelExecutive Director of Legal
- Mr. Ryan CraigVice President of Marketing
- Mr. John AikenExecutive Director of People Management & Training
- Dr. John C. Arthur Ph.D.Senior Vice President of Manufacturing & Supply
- Mr. Robert SullivanSenior Vice President of Oncology Care Franchise & Commercial Operations
- Mr. Brett FleshmanChief Business Officer